Cargando…
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Modern disease-modifying therapies (DMTs) in multiple sclerosis (MS) have variable modes of action and selectively suppress or modulate the immune system. In this review, we summarize the predicted and intended as well as unwanted adverse effects on leukocytes in peripheral blood as a result of trea...
Autores principales: | Schweitzer, F., Laurent, S., Fink, G. R., Barnett, Michael H., Hartung, H. P., Warnke, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217029/ https://www.ncbi.nlm.nih.gov/pubmed/32036423 http://dx.doi.org/10.1007/s00415-019-09690-6 |
Ejemplares similares
-
Health economics of disease-modifying therapy for multiple sclerosis in the United States
por: Hartung, Daniel M.
Publicado: (2021) -
Multiple Sclerosis, Disease-Modifying Therapies, and Infections
por: Langer-Gould, Annette M., et al.
Publicado: (2023) -
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011) -
Disease Modifying Therapy in Multiple Sclerosis
por: Williams, U. E., et al.
Publicado: (2014) -
Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2009)